Edward Greeno, MD

Edward Greeno
green048@umn.edu
612-625-9604

420 Delaware Street SE
MMC 480
Minneapolis, MN 55455
United States

Websites
Experts@Minnesota Profile
PubMed article list

Dr. Greeno received his M.D. in 1986 from Case Western Reserve University followed by internal medicine residency training and hematology subspecialty training at the University of Minnesota. He is board certified in Internal Medicine, Hematology, and Medical Oncology. He served as director of Hematology/Oncology at Hennepin County Medical Center prior to recruitment at the University of Minnesota. Dr. Greeno is the Medical Director of the Masonic Cancer Clinic at the University of Minnesota.He is also Executive Medical Director of University of Minnesota Cancer Care. He has conducted numerous human trials of cancer therapeutics, including an ongoing first in human study of Minnelide, a drug developed from a natural product at the University of Minnesota for pancreatic cancer.

Education

Professor of Medicine, Division of Hematology, Oncology and Transplantation

Chief, Cancer Care, Masonic Cancer Center (MCC)

 

Hematologist / Oncologist

Medical School, Case Western Reserve University School of Medicine, Cleveland, OH

Residency, University of Minnesota, Minneapolis, MN

Fellowship, University of Minnesota, Minneapolis, MN

Expand all

Summary

Awards & Recognition

  • Mpls St. Paul Magazine "Top Doctor" (2013-2015)
  • "Best Doctors for Women," Minnesota Monthly, 2014
  • Best Doctors in America® (2011-2012, 2013)
  • Clinical Excellence Award, University of Minnesota Medical School (2010)
  • Medical Staff Award, Fairview-University Medical Center (2004, 2005)
  • Minnesota Monthly "Best Doctor" (2014)

Professional Associations

  • Education Director, Division of Hematology, Oncology and Transplant (2000-2007)
  • Medical Director, Anticoagulation Clinic, Hennepin County Medical Center (1995-1998)
  • Division Chief, Hematology/Oncology, Hennepin County Medical Center (1997-1998)
  • Executive Medical Director, University of Minnesota Cancer Care (2011-present)

Research

Publications

  • Mitra AK, Kirstein MN, Khatri A, Skubitz KM, Dudek AZ, Greeno EW, Kratzke RA, Lamba JK. Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors. Pharmacogenomics. 2012; 13(9):1009-21.
  • Picozzi VJ, Abrams RA, Decker PA, Traverso W, O'Reilly EM, Greeno E, Martin RC, Wilfong LS, Rothenberg ML, Posner MC, Pisters PW; American College of Surgeons Oncology Group. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b–based chemoradiation: ACOSOG Trial Z05031. Ann Oncol. 2011 Feb;22(2):348-54.
  • Bardia A, Greeno E, Miller R, Alberts S, Dozois E, Haddock M, Limburg P. Is a solitary inguinal lymph node metastasis from adenocarcinoma of the rectum really a metastasis? Colorectal Dis. 2010 Apr;12(4):312-5.
  • Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res. 2006; 118:555-68. Review. PMID: 16388837
  • Knutsen A, Sielaff TD, Greeno E, Tuttle TM. Staged laparoscopic infusion of hyperthermic intraperitoneal chemotherapy after cytoreductive surgery. J Gastrointest Surg. 2006; 10:1038-43. PMID: 16843875
  • Tuttle TM, Zhang Y, Greeno E, Knutsen A. Toxicity and quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2006; 13:1627-32. PMID: 17013686
  • Greeno E, McCullough J, Weisdorf D. Platelet utilization and the transfusion trigger: a prospective analysis. Transfusion. 2007; 47:201-5. PMID: 17302764
  • Kapoor BS, Hunter DW, Greeno E, Pambuccian S, Sielaff T. Hepatic encephalopathy secondary to transtumoral portal-hepatic venous shunting. Hepatogastroenterology 2003; 50:4-7.
  • Bloom SH, Coad JE, Greeno EW, Ashrani AA, Hammerschmidt DE. Cholecystitis as the presenting manifestation of acute myeloid leukemia: report of a case. Am J Hematol 2002; 70:254-256.
  • Kosari K, Gomes M, Hunter D, Hess DJ, Greeno E, Sielaff TD. Local, intrahepatic, and systemic recurrence patterns after radiofrequency ablation of hepatic malignancies. J Gastrointest Surg 2002; 6:255-263.

Clinical

Clinics

Masonic Cancer Center

Board Certifications

American Board of Internal Medicine

Clinical Interests

GI malignacies, Colon cancer